Ocular Therapeutix Inc (OCUL) concluded trading on Wednesday at a closing price of $10.76, with 4.84 million shares of worth about $52.06 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 22.83% during that period and on July 09, 2025 the price saw a gain of about 8.47%. Currently the company’s common shares owned by public are about 159.26M shares, out of which, 133.28M shares are available for trading.
Stock saw a price change of 18.24% in past 5 days and over the past one month there was a price change of 19.29%. Year-to-date (YTD), OCUL shares are showing a performance of 61.32% which increased to 26.00% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $5.78 but also hit the highest price of $11.77 during that period. The average intraday trading volume for Ocular Therapeutix Inc shares is 2.12 million. The stock is currently trading 18.24% above its 20-day simple moving average (SMA20), while that difference is up 29.56% for SMA50 and it goes to 26.64% higher than SMA200.
Ocular Therapeutix Inc (NASDAQ: OCUL) currently have 159.26M outstanding shares and institutions hold larger chunk of about 74.32% of that.
The stock has a current market capitalization of $1.71B and its 3Y-monthly beta is at 1.47. It has posted earnings per share of -$1.15 in the same period. It has Quick Ratio of 10.14 while making debt-to-equity ratio of 0.29. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for OCUL, volatility over the week remained 5.05% while standing at 5.74% over the month.
Stock’s fiscal year EPS is expected to drop by -17.19% while it is estimated to increase by 2.56% in next year. EPS is likely to shrink at an annualized rate of 4.11% for next 5-years, compared to annual growth of 8.51% made by the stock over the past 5-years.
Coverage by RBC Capital Mkts stated Ocular Therapeutix Inc (OCUL) stock as an Outperform in their note to investors on March 18, 2025, suggesting a price target of $17 for the stock. Stock get a Buy rating from TD Cowen on June 20, 2024.
